NHS Launches Major Trial for Early Cancer Detection

The STRIDE-RCT trial evaluates four distinct blood tests: Enlighten, PinPoint, Signatera, and Halo. These tests analyze circulating biomarkers and tumor DNA, offering new avenues for detection.

The Signatera test already detects recurrent cancer. The Halo test focuses on analyzing single extracellular vesicles, pushing the boundaries of diagnostic science.

The Enlighten test measures circulating amino acid biomarkers and uses AI. Proteotype claims it examines patterns of these biomarkers to assess the possibility of breast, bowel, lung, or prostate cancer.

The Pinpoint AI test combines weak cancer signals in the blood to generate one strong test result. Work so far suggests it can pick up signs of bowel, ovarian, lung, pancreatic, liver, bile duct, and stomach cancer.

Patients provide one or two tubes of blood at their GP practice, alongside routine tests. Scientists behind the technology say these tests pick up signals in the blood that indicate whether further investigation for suspected cancer is needed, or if the patient can be safely ruled out.

James Frith called the initiative an "exciting and world-first major trial for earlier diagnoses for abdominal cancers, which are notoriously hard to spot, very often because their symptoms can be misread as something other than cancer." Michelle Mitchell added that "GPs have long needed better tools to help them navigate that uncertainty by identifying which patients require further testing and this trial in England is an important step towards addressing that need."

Around 71,000 people in England receive a diagnosis each year for pancreatic, stomach, liver, ovarian, or bowel cancer. Nearly 35,000 die from these diseases. Yvette Cooper stated, "The earlier cancers are diagnosed, the more chance they can be successfully treated, and lives can be saved."

NHS Health Leaders hope the innovative trial will streamline NHS capacity. It aims to avoid unnecessary invasive hospital referrals and improve patient survival rates. Peter Johnson noted, "We are at the start of revolution in cancer diagnosis, and this trial will help us to find out whether blood tests can help GPs get the right patients to the right tests sooner, supporting earlier diagnosis when treatment is most likely to be successful."

A positive result from these tests does not automatically mean cancer is present. A negative result is not a guaranteed all-clear. The trial continues to evaluate the efficacy and implications of these advanced diagnostic tools.